SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is ...

Robert Blum. The likelihood now is that Cytokinetics will have to re-align itself around aficamten, currently in the SEQUOIA-HCM pivotal trial which is due to generate results later in 2023 ...

In the press release trumpeting the latest aficamten arrangement, Cytokinetics waxed enthusiastic about the suitability of Sanofi as a partner. It quoted CEO Robert Blum as saying that " We now ...

Cytokinetics should hear back from the FDA ... In the company's third-quarter results update, chief executive Robert Blum said that aficamten has a "next-in-class safety and efficacy profile ...

with results expected in the first half of this year as may potentially support the use of aficamten as monotherapy,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer.

the validation of the MAA marks an important milestone in bringing this potential medicine to even more patients with HCM worldwide,” said Robert I. Blum, Cytokinetics’ President and Chief ...

“We have enjoyed a productive collaboration with CORXEL and appreciate all they have done to advance aficamten in Greater China,” said Robert I. Blum, Cytokinetics’ President and CEO.

Inspire Investing LLC boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.8% in the ...

SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale.

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq ... medicines to patients around the world,” said Mr. Blum. “Vision 2030 articulates ambitious company goals to deliver product ...